LIFE Science Hub
JOURNAL OF SCIENCE
EXPANDING KNOWLEDGE ABOUT NUTRITION AND HEALTH

ORIGINAL RESEARCH
ISSN 2845-7501

RNAi-mediated silencing of HIF-1α improves lupus development in MRL/lpr mice - Evidence review

D.ssa M. Mondini[1]

1 Biologist, Italy

1. ABSTRACT

The original study evaluated whether reducing HIF-1α, a protein that helps cells adapt to low-oxygen conditions and modulates immune metabolism, could attenuate lupus in MRL/lpr mice. Treatment with a small RNA designed to decrease HIF-1α reduced blood levels of IL-17 and was associated with lower anti-nucleosome autoantibodies, lower urinary protein, reduced renal deposits of immunoglobulin G and complement C3, and improved renal histology. The available material is only the abstract; therefore, it does not report sample sizes, dosages, complete numerical values, or a direct measurement of Th17 cells.In "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, the publication contributes to the narrative that HIF-1α supports a pro-inflammatory Th17 immune response and kidney damage in lupus. Independent evidence confirms the biological link between HIF-1α, Th17 differentiation, and IL-17, shows an association in T cells of people with lupus, and reproduces an improvement in lupus-like disease in mouse models through metabolic reduction of HIF-1α. However, clinical trials demonstrating that inhibiting HIF-1α is effective or safe in human lupus remain absent.

ONLINE ARTICLE

ARTICLE INFORMATION

Published: November 25, 2026
Updated: November 25, 2026

DOI 10.5281/zenodo.24529890

MISSION

LIFE Science Hub – Journal of Science was founded with the aim of making scientific knowledge accessible without giving up methodological rigour, quality of sources and authoritativeness of content. The journal promotes the dissemination of knowledge in the health, nutrition, medical and longevity sciences, building a bridge between the world of research and society.

Through articles, reviews, in-depth analyses and expert contributions, the Journal champions evidence-based medicine and science, fostering a correct interpretation of scientific data and countering misinformation. Every piece of content is developed with the aim of translating the complexity of research into understandable, useful and applicable information, while keeping intact the principles of accuracy, transparency and scientific independence.

Free from political, industrial and commercial influence, the journal stands as an authoritative and independent editorial space, dedicated to promoting scientific culture, professional development and the growth of health awareness among the public.

2. ANALYZED STUDY

The research question was whether the experimental reduction of HIF-1α could modify the course of lupus in a mouse model predisposed to the disease. The hypothesis stems from the fact that HIF-1α does not only respond to oxygen scarcity: in immune cells, it can promote the rapid use of glucose and support inflammatory programs, including the formation of Th17 cells. Th17 cells are T lymphocytes that produce, among other molecules, interleukin-17 or IL-17, a cytokine that can contribute to the inflammatory response.The relevance to "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi therefore concerns a specific segment of the narrative: HIF-1α immune activity related to IL-17 lupus-associated kidney damage. The study analyzed verifies this segment in MRL/lpr mice, but it cannot establish that the same intervention cures lupus in humans. Furthermore, the only available abstract does not report direct quantitative measurements of the frequency of Th17 cells; however, a reduction of IL-17 in the serum is documented.

3. MATERIALS AND METHODS OF THE ORIGINAL STUDY

The research is an in vivo experiment, meaning it was conducted in living animals, specifically the MRL/lpr mouse model, which is commonly used to study lupus-like manifestations. The authors administered HIF1a-shRNA, a small hairpin RNA designed to reduce the expression of the HIF1A gene through the RNA interference mechanism. In simple terms, the intervention aims to make cells produce less HIF-1a.The outcomes evaluated included HIF-1a, serum IL-17, anti-nucleosome antibodies, urinary protein concentration, histological alterations of the kidney, and renal deposits of IgG and C3. IgG is an antibody; C3 is a complement protein, part of an immune system that can amplify inflammation. The control group is mentioned in the abstract, but its composition is not reported in the available material. Furthermore, the number of animals, sex, age, dosage schedule, route of administration, experimental period, inclusion criteria, statistical methods, and threshold values for significance are not reported in the available material.

4. RESULTS

In mice treated with HIF1a-shRNA, the serum concentration of IL-17 was reduced compared to controls. In plain language, the decrease in HIF-1a was accompanied by a lower circulating presence of a molecule that supports inflammation. The abstract does not report the absolute values, percentage variations, confidence intervals, or P-values for this comparison.The treated group also showed a reduction in anti-nucleosome antibodies, lower protein concentrations in the urine, less damage observed in renal tissues, and a marked reduction in IgG and C3 deposits in the kidney. Proteinuria, which is the increased presence of protein in the urine, is an indicator consistent with damage to the renal filtration barrier. Deposits of immune complexes and complement can contribute to kidney inflammation in lupus. For these results as well, the abstract alone does not provide numerical values, effect sizes, or detailed statistical analyses.The passage most directly relevant to the book's paragraph is therefore the sequence observed in the animal model: reduction of HIF-1a, decrease in serum IL-17, and attenuation of multiple indicators of kidney damage. The available material, however, does not allow for a quantitative verification of the claim regarding a significant reduction of Th17 cells in the treated mice.

5. INTERPRETATION

The result suggests that HIF-1α plays a role in maintaining an immune and metabolic environment that favors inflammation in murine lupus. When HIF-1α was reduced, blood IL-17 levels also decreased, and indicators consistent with autoimmunity and kidney damage were reduced. This is consistent with the idea that a T cell, when receiving specific metabolic signals, can be oriented toward a more inflammatory Th17 program.From a biological perspective, the proposed link is HIF-1α activation of Th17 programs and IL-17 production increased inflammation and organ damage. The analyzed study directly documents the first and last parts in treated mice through the reduction of HIF-1α, IL-17, and renal markers. However, it does not prove that the decrease in IL-17 is the sole cause of the renal improvement: silencing HIF-1α can simultaneously modify multiple cell types and biological pathways.The research is not

equivalent to a therapeutic trial in humans. An MRL/lpr model reproduces important aspects of lupus, but not the full clinical complexity of the human disease. Furthermore, the use of experimental interfering RNA does not allow for the deduction of doses, long-term efficacy, or the safety of potential HIF-1α inhibition in patients.

6. INDEPENDENT SUPPORTING EVIDENCE

Initial confirmation of the HIF-1α Th17 IL-17 biological pathway comes from an independent experiment on murine T cells and a model of nervous system autoimmunity. Dang and colleagues showed that HIF-1α promotes the development of Th17 cells by activating RORγt, a genetic regulator necessary for their differentiation, and by supporting the expression of IL-17. In mice lacking HIF-1α in T cells, fewer IL-17-producing cells, more regulatory T cells, and reduced severity of experimental autoimmune disease were observed [1]. This evidence is strong regarding the cellular mechanism, but it does not concern lupus nor does it demonstrate a therapeutic effect in humans.A second study brought this connection into the context of human lupus. Liao and colleagues found higher expression of HIF-1α in CD4-positive T cells from people with systemic lupus erythematosus compared to the controls studied. HIF-1α expression was positively associated with genes of glycolysis and the IL-17 pathway; furthermore, experimentally increasing HIF-1α in murine T cells promoted Th17 differentiation [2]. The data in humans is observational: it indicates a consistent relationship, but it does not prove that the increase in HIF-1α is the initial cause of lupus or its organ damage.A third study linked the same metabolic network to lupus-like manifestations. Kono and colleagues treated MRL/lpr mice with BPTES, an inhibitor of the glutaminase 1 enzyme, reducing a pathway by which cells use glutamine. The treatment improved disease indicators in a Th17-dependent manner; in the mice, renal infiltration of immune cells and IL-17-producing T cells decreased. In T cell cultures from six people with lupus, BPTES reduced Th17 differentiation; the authors also observed a reduction in glycolysis and the HIF-1α protein [3]. This study does not directly block HIF-1α, thus it indirectly confirms the metabolic link; however, it reproduces the expected direction in a lupus model: lower HIF-1α and a reduced Th17 program are accompanied by lower disease activity.

7. CONFLICTING EVIDENCE

No directly conflicting evidence sufficiently relevant to the direction observed in the mouse model—namely, that an experimental reduction of HIF-1α can attenuate inflammatory and renal markers in experimental lupus—has been identified. However, there is an important element of caution: HIF-1α does not appear to behave as a uniform indicator of inflammatory activity in all clinical contexts.In an observational study conducted on 42 people with lupus nephritis and 30 healthy controls, urinary HIF-1α was higher in people with lupus nephritis and was associated with greater histological chronicity and lower estimated renal filtration. However, it was not correlated with the histological activity index, proteinuria, anti-double-stranded DNA antibodies, complement, or the overall lupus activity score [4]. This result does not negate the possible biological role of HIF-1α, but it shows that in humans, its value may primarily reflect hypoxia and chronic kidney damage, rather than directly measuring active inflammation or predicting treatment response on its own.

8. QUADRO COMPARATIVO E SINTESI DELLE EVIDENZE

The table distinguishes the publication that is the subject of the review from the independent research used to verify the book's narrative passage.

Quadro comparativo

Reference	Study type	Population or model	Main result	Direction of evidence	Strength of evidence
Original study	Animal, in vivo intervention	MRL/lpr mice	Silencing of HIF-1α reduced serum IL-17 and markers of autoimmunity and kidney damage.	direct confirmation	moderate
[1]	Cellular and animal, genetic intervention	Murine T cells and murine model of Th17-dependent autoimmunity	HIF-1α deficiency in T cells reduced Th17 and IL-17 and increased Treg.	indirect confirmation	moderate
[2]	Human and cellular observational	T cells from people with lupus and murine T cells	HIF-1α was increased in lupus T cells and associated with glycolytic genes and IL-17; its overexpression promoted Th17.	biologically consistent evidence	moderate
[3]	Animal, cellular, and ex vivo cultures	MRL/lpr mice and T cells from six people with lupus	Glutaminase inhibition reduced HIF-1α, glycolysis, and Th17 differentiation, improving lupus-like disease.	indirect confirmation	moderate
[4]	Cross-sectional observational	42 people with lupus nephritis and 30 healthy controls	Urinary HIF-1α was increased and associated with chronicity, but not with histological activity or proteinuria.	discordant evidence	low

9. SINTESI EDITORIALE E CONCLUSIONI

CONCLUSIONS

The study analyzed shows that experimentally reducing HIF-1α in MRL/lpr mice is accompanied by a decrease in IL-17 and an improvement in several renal and autoimmune indicators. The narrative linking HIF-1α to the Th17 program and inflammation is moderately supported by mechanistic evidence, other animal models, and observations in T cells from people with lupus. However, the therapeutic hypothesis in humans remains preliminary: the available results do not allow for the inhibition of HIF-1α to be considered a proven treatment for lupus.

Aggiornato al 25/11/2026. Questo contenuto riflette una sintesi divulgativa delle evidenze scientifiche al momento della pubblicazione e non sostituisce il parere medico.

10. TRANSPARENCY AND SCIENTIFIC RESPONSIBILITY

Artificial Intelligence was used solely as a tool for editorial and documentary support. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subjected to independent peer review prior to publication.

To ensure the greatest transparency, the complete history of the article, including the dates of submission, revision, acceptance and publication, as well as information on the peer review process, is available on the dedicated Article History page.

11. RIFERIMENTI BIBLIOGRAFICI

[1] **Increased HIF-1a expression in T cells and associated with enhanced Th17 pathway in systemic lupus erythematosus**
Liao et al., 2022
Journal of the Formosan Medical Association
DOI: https://doi.org/10.1016/j.jfma.2022.05.003

[2] **Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus like Disease in MRL / lpr Mice and Experimental Autoimmune Encephalomyelitis**
Kono et al., 2019
Arthritis & Rheumatology
DOI: https://doi.org/10.1002/art.41019

[3] **Urinary Hypoxia-Inducible Factor-1alpha Levels Are Associated with Histologic Chronicity Changes and Renal Function in Patients with Lupus Nephritis**
Ma et al., 2012
Yonsei Medical Journal
DOI: https://doi.org/10.3349/ymj.2012.53.3.587

[4] **Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1**
Dang et al., 2011
Cell
DOI: https://doi.org/10.1016/j.cell.2011.07.033